Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 705 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 705 shares of Natera stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $89.55, for a total value of $63,132.75. Following the completion of the sale, the chief financial officer now owns 71,397 shares in the company, valued at $6,393,601.35. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The shares were sold at an average price of $91.38, for a total value of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.
• On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total transaction of $1,509,092.13.
• On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total value of $210,566.15.

Natera Trading Up 0.4 %

NASDAQ NTRA opened at $91.66 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The firm has a 50 day simple moving average of $87.72 and a 200-day simple moving average of $67.16. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. As a group, equities analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NTRA. YHB Investment Advisors Inc. purchased a new position in shares of Natera in the 1st quarter valued at about $36,000. Mesirow Financial Investment Management Inc. purchased a new stake in shares of Natera during the first quarter worth approximately $2,173,000. Simplicity Wealth LLC acquired a new stake in Natera in the first quarter valued at approximately $223,000. Fifth Third Bancorp lifted its stake in Natera by 3.5% in the first quarter. Fifth Third Bancorp now owns 6,432 shares of the medical research company’s stock worth $588,000 after acquiring an additional 216 shares during the last quarter. Finally, Arcadia Investment Management Corp MI grew its holdings in Natera by 47.8% during the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after acquiring an additional 174 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and boosted their price objective for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. Stephens reissued an “overweight” rating and issued a $78.00 price objective on shares of Natera in a report on Tuesday, January 30th. Canaccord Genuity Group lifted their target price on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Piper Sandler increased their price target on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Finally, The Goldman Sachs Group lifted their price target on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.